Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.37 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.37 |
| ▸ | PLA2G2F | Q9BZM2 | 1/20 | 0.37 |
| ▸ | PLA2G2E | Q9NZK7 | 1/20 | 0.37 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6983468 | 0.88 | HTR6 (0.51) | HTR6PLA2G2ATSPO | |
| SCHEMBL6694888 | 0.88 | HTR6 (0.51) | HTR6PLA2G2ATSPO | |
| SCHEMBL6982832 | 0.84 | HTR6 (0.46) | HTR6PLA2G2AFABP4TSPO | |
| SCHEMBL6982837 | 0.84 | HTR6 (0.46) | HTR6PLA2G2AFABP4TSPO | |
| SCHEMBL29862597 | 0.83 | PLA2G2A (0.51) | HTR6PLA2G2A | |
| SCHEMBL818729 | 0.83 | PLA2G2A (0.51) | HTR6PLA2G2A | |
| SCHEMBL819415 | 0.83 | PLA2G2A (0.51) | HTR6PLA2G2A | |
| SCHEMBL29862369 | 0.83 | PLA2G2A (0.51) | HTR6PLA2G2A | |
| SCHEMBL818313 | 0.81 | PLA2G2A (0.53) | HTR6PLA2G2A | |
| SCHEMBL29862401 | 0.81 | PLA2G2A (0.53) | HTR6PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | OPHIREX INC (US) | 2022-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220370411-A1 | EARLY MANAGEMENT, MITIGATION and PREVENTION OF SEPSIS and SEPSIS-LIKE SYNDROMES, INCLUDING NEO-NATAL ARDS DUE TO INFECTION, INJURY or IATROGENESIS | PLA2G12A, PLA2G3, PLA2G1B | HTR6 2139/4885PLA2G2A 14/4885FABP4 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.